Cargando…

Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach

BACKGROUND: The approval of direct-acting antivirals for Interferon-free treatment revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two treatment regimens for genotype 1 infection received conditional approval in the European Union: Sofosbuvir and Ribavirin for 24 week...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gissel, Christian, Götz, Georg, Mahlich, Jörg, Repp, Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520276/ https://www.ncbi.nlm.nih.gov/pubmed/26223310 http://dx.doi.org/10.1186/s12879-015-1048-z

Ejemplares similares

Cost per responder of TNF-α therapies in Germany
por: Gissel, Christian, et al.
Publicado: (2013)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
por: Gissel, C., et al.
Publicado: (2017)

Assessing Telemedicine Efficiency in Follow-up Care With Video Consultations for Patients in Orthopedic and Trauma Surgery in Germany: Randomized Controlled Trial
por: Muschol, Jennifer, et al.
Publicado: (2022)

Cost Effectiveness of Voretigene Neparvovec for RPE65-Mediated Inherited Retinal Degeneration in Germany
por: Uhrmann, Matthias Fritz, et al.
Publicado: (2020)

Economic and Environmental Impact of Digital Health App Video Consultations in Follow-up Care for Patients in Orthopedic and Trauma Surgery in Germany: Randomized Controlled Trial
por: Muschol, Jennifer, et al.
Publicado: (2022)

Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus: A structural equation modeling approach
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data
por: Mahlich, Jörg, et al.
Publicado: (2015)

COVID-19 pandemic and waiting times in outpatient specialist care in Germany: an empirical analysis
por: Muschol, Jennifer, et al.
Publicado: (2021)

Unemployment, health, and education of HIV-infected males in Germany
por: Groß, Mona, et al.
Publicado: (2015)

Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison
por: Andersohn, Frank, et al.
Publicado: (2016)

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1
por: Linas, Benjamin P., et al.
Publicado: (2016)

Efficiency in COVID-19 Vaccination Campaigns—A Comparison across Germany’s Federal States
por: Götz, Georg, et al.
Publicado: (2021)

Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines
por: Treskova, Marina, et al.
Publicado: (2016)

Guarding the frontiers: the biology of type III interferons
por: Wack, Andreas, et al.
Publicado: (2015)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Approaches for Efficiently Detecting Frontier Cells in Robotics Exploration
por: Quin, Phillip, et al.
Publicado: (2021)

Applying frontier approach to measure the financial efficiency of hospitals
por: Wu, Jih-Shong
Publicado: (2023)

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
por: Mahlich, Jörg, et al.
Publicado: (2017)

COVID-19 related decline in cancer screenings most pronounced for elderly patients and women in Germany: a claims data analysis
por: Muschol, Jennifer, et al.
Publicado: (2022)

Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach
por: Sruamsiri, Rosarin, et al.
Publicado: (2017)

Artificial intelligence in medical education and the meaning of interaction with natural intelligence – an interdisciplinary approach
por: Lang, Johannes, et al.
Publicado: (2020)

Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach
por: Mahlich, Jörg, et al.
Publicado: (2019)

Persistent Cost Efficiency at Public Community Colleges in the US: A Stochastic Frontier Analysis
por: Titus, Marvin A., et al.
Publicado: (2021)

Estimating the NIH Efficient Frontier
por: Bisias, Dimitrios, et al.
Publicado: (2012)

Quality and resource efficiency in hospital service provision: A geoadditive stochastic frontier analysis of stroke quality of care in Germany
por: Pross, Christoph, et al.
Publicado: (2018)

Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier
por: Jakobs, Florian, et al.
Publicado: (2022)

Estimation of Tinnitus-Related Socioeconomic Costs in Germany
por: Tziridis, Konstantin, et al.
Publicado: (2022)

Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
por: Ferreira, Vinicius Lins, et al.
Publicado: (2020)

Smoke-free homes: The final frontier
por: Huque, Rumana, et al.
Publicado: (2021)

Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
por: Venugopal, Vishnu, et al.
Publicado: (2018)

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies
por: Krauth, Christian, et al.
Publicado: (2019)

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Hepatitis C Virus Infection: Looking for Interferon Free Regimens
por: González-Moreno, J., et al.
Publicado: (2013)

The New Era of Interferon-Free Treatment of Chronic Hepatitis C
por: Solbach, Philipp, et al.
Publicado: (2015)

Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Resampled Efficient Frontier Integration for MOEAs
por: Quintana, David, et al.
Publicado: (2021)

Stochastic Frontier Model Approach for Measuring Stock Market Efficiency with Different Distributions
por: Hasan, Md. Zobaer, et al.
Publicado: (2012)

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany
por: Mahlich, Jörg, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fkqsi9en3acjgl8vjabj94ui0l